Get Involved: Cancer Nanomedicine Co-ops for Undergraduate Research Experience
Interested in learning how nanomedicine is used to detect and treat cancer? Want to get involved in developing new nanotechnologies for the clinic? We are looking to match undergrads at Northeastern University with leading Boston researchers and clinicians for a six-month, hands-on research experience. If you are thinking about a career in cancer science, engineering, or medicine, come get involved in the world’s first undergraduate program in cancer nanomedicine! We are now accepting applications for the January-June 2017 co-op period through October 17, 2016. Applications may be submitted through NUcareers. Join us for an info session on September 20 @ 6 pm (Snell Library 33) or October 5 @ 6 pm (Snell Library 33). We will also be hosting a booth at the BIOE/AIChE Career Fair on September 27 @ 6:30pm (Fenway 378). See the full job description here.
G Mike Makrigiorgos, Ph.D.
Professor of Radiation Oncology, HMS
We apply nanoparticle-based approaches for DNA molecular diagnostics, PCR-based detection of DNA alterations, as well as the enrichment and identification of cancer biomarkers from blood-circulating DNA/RNA. We also combine site-specific image-guided irradiation with nanoparticle based approaches for enhancing detection of circulating biomarkers via ‘liquid biopsy’.
Ross I Berbeco, Ph.D.
Associate Professor of Radiation Oncology, HMS
Our lab performs theoretical and experimental studies of systemically administered nanoparticles and their role in enhancing radiation therapy for cancer treatment. Students will have the opportunity to functionalize these particles with tumor-specific targeting moieties and study how this leads to localized disruption of the tumor vasculature.
Biomedicial Physics, '17
Implementation of novel MR-based attenuation correction in PET/MR pelvic scans
Radiotherapeutic synergism of thermogelling cisplatin-loaded polymers for cervical cancer treatment
Behavioral Neurosci, '19
Assessing the reproducibility of MRI-based brain tumor measurements between both observers and MRI vendors